Vanda: VPO-227 Advancement Signals More Upsides

Summary

• From the commercialization front, Vanda Pharmaceuticals is taking prudent steps to boost Hetlioz and Fanapt sales.
• The company recently planted long-term growth via the OliPas partnership for ASO development.
• Additionally, Vanda is advancing VPO-227 with UCSF for its first indication as a treatment for cholera.

Does the company have a short-range or long-range outlook in regard to profits? - Phillip Fisher (The Father of Growth Investing)

Author's Note:?This article is an abridged version of an article originally published for members?of the Integrated BioSci Investing marketplace on October 24, 2022.

As special investments, growth biotech companies are usually hit the hardest amid a bear market. Nevertheless, they rebound the most vigorously during a bullish cycle to give you the strongest alpha returns in the long haul. As such, it made sense for you to focus on growth biotech if you have a long-term investment horizon. As you hold growth bio-stocks, make sure you keep tabs on different growth initiatives (i.e., catalysts) for you to make proper adjustments to your holding.

One such growth stock is?Vanda?Pharmaceuticals (NASDAQ:VNDA). During this bear market, the stock is trading near its cash position while the company is turning up all growth engines (both short and long-term). In this research, I'll feature a fundamental analysis of Vanda while focusing on the latest growth catalyst that is centering on an early-phase molecule dubbed VPO-227.

YOU CAN EITHER READ THE 1)?FREE ARTICLE?ON SEEKING ALPHA OR 2)?IN-DEPTH ANALYSIS?INSIDE INTEGRATED BIOSCI INVESTING.